CD8A and neoplasm: Finally, we assessed the tumor suppressive effect of a licensed SARS-CoV-2 mRNA vaccine and an MHC-I-restricted spike immunodominant epitope after intratumoral delivery and the recall of anti-SARS-CoV-2-specific CD8+ T cells.